Pancreatic cancer patients taking daraxonrasib in combination with standard chemotherapy doubled their survival time, according to new trial data. The daily oral medication represents a genuine advance in treating the disease, which carries a five-year survival rate below 12 percent across all stages.
Daraxonrasib works by inhibiting a protein pathway implicated in tumor growth and resistance to chemotherapy. Patients receiving the drug alongside gemcitabine and nab-paclitaxel, the current standard treatment regimen, showed median overall survival extending from roughly 9 months to 18 months. Response rates also improved, with more patients experiencing tumor shrinkage.
The results mark a watershed moment for pancreatic oncology. This cancer kills faster than any other major malignancy. Historically, treatment options have been limited, with most patients diagnosed at advanced stages when surgery becomes impossible. Chemotherapy alone delivers modest benefits.
Daraxonrasib targets KRAS mutations, which occur in roughly 90 percent of pancreatic cancer cases. Previous attempts to block KRAS therapeutically failed, making this drug class a long-awaited breakthrough. The compound belongs to a new generation of KRAS inhibitors that finally achieved clinical efficacy.
Regulatory approval and insurance coverage remain pending, but oncologists expect rapid progression. The drug will likely enter standard-of-care protocols within months of authorization. Analysts predict it could reshape treatment for other KRAS-driven cancers, including colorectal and lung cancers.
Cost and accessibility will shape real-world impact. Pancreatic cancer disproportionately affects lower-income populations, who may face barriers to obtaining this therapy. Patient advocacy groups are already pushing manufacturers and payers to ensure broad access.